Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 23 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung CancerNot yet recruitingNCT05414630Phase 2
• Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCCRecruitingNCT05414032Phase 2
• mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCRecruitingNCT05412589Phase 2
• Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2
• the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaRecruitingNCT05408221Phase 2/3
• A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionRecruitingNCT05407519Phase 2
• ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsRecruitingNCT05405595Phase 1/2
• Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder CancerRecruitingNCT05401279Phase 2
• Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.RecruitingNCT05397769Phase 2
• Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCCRecruitingNCT05394415Phase 1/2
• PD1 and PARP for Maintenance Therapy in NSLLCRecruitingNCT05392686Phase 2
• Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced GastricNot yet recruitingNCT05387681Phase 2
• AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung CancerRecruitingNCT05377658Phase 2
• Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckEnrolling by invitationNCT05376553Phase 1
• Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma PatientsRecruitingNCT05374252Phase 3
• Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular CarcinomaRecruitingNCT05366829Phase 2
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2
• A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLCEnrolling by invitationNCT05360979Phase 2
• Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal CancerRecruitingNCT05360277Phase 2
• PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)RecruitingNCT05357846Phase 3
• A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）RecruitingNCT05357651Phase 1
• To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersRecruitingNCT05356741Phase 1/2
• A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT05355051Phase 2
• Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard TherapyNot yet recruitingNCT05350917Phase 2
• Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System LymphomaNot yet recruitingNCT05347641Phase 2
• Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal CarcinomaRecruitingNCT05342792Phase 3
• Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyRecruitingNCT05342194Phase 3
• A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory LymphomaRecruitingNCT05341557Phase 1
• PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT05341193Phase 1/2
• Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Phase 3
• Study of PAT in Patients With Solid Tumor CancersRecruitingNCT05338658Phase 1
• Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal CancerNot yet recruitingNCT05333809Phase 2
• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingNCT05333458Phase 2
• Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
• Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT05318469Phase 1/2
• Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
• Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder CancerRecruitingNCT05312671Phase 2
• Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCRecruitingNCT05310643Phase 2
• Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARCRecruitingNCT05307198Phase 2
• Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
• Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabEnrolling by invitationNCT05303532Phase 3
• A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT05297552Phase 2
• Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung CancerRecruitingNCT05296603Phase 2
• Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBRecruitingNCT05295212Phase 2
• CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge StrategyRecruitingNCT05291156Phase 2
• A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)RecruitingNCT05286619Phase 2
• Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerRecruitingNCT05284539Phase 2
• Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)RecruitingNCT05281003Phase 2
• First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPNot yet recruitingNCT05280626Phase 2
• Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 1
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKRecruitingNCT05266846Phase 2
• A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.RecruitingNCT05263180Phase 1
• Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)RecruitingNCT05259319Phase 1
• Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular FeaturesRecruitingNCT05255653Phase 3
• Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT05252078Phase 2
• TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCRecruitingNCT05250843Phase 2/3
• Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment FailureNot yet recruitingNCT05248022Not applicable
• Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal CancerRecruitingNCT05245474Phase 2
• Sintilimab Plus NCT or NCRT Versus NCRT for ESCCNot yet recruitingNCT05244798Phase 3
• A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's LymphomaRecruitingNCT05244642Phase 3
• Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon CancersRecruitingNCT05239546Phase 2
• Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric AdenocarcinomaRecruitingNCT05237349Phase 2
• PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal CancerRecruitingNCT05236972Phase 3
• A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric CancerRecruitingNCT05235906Phase 2
• The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With PembrolizumabRecruitingNCT05235737Phase 4
• PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05234307Phase 1
• Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic CancerRecruitingNCT05232409Phase 1
• A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.Not yet recruitingNCT05231850Phase 2
• Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingNCT05222971Phase 2
• A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCRecruitingNCT05221658Phase 2
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingNCT05218889Phase 1/2
• Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic CancerRecruitingNCT05218629Phase 2
• SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaNot yet recruitingNCT05218148Phase 2
• A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) CancerRecruitingNCT05216237Phase 2
• Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Phase 2
• Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2
• Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder CancerRecruitingNCT05203913Phase 2
• Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLCRecruitingNCT05203276Phase 2
• A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade ChondrosarcomaRecruitingNCT05193188Phase 2
• Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.RecruitingNCT05189483Phase 2
• Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
• First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaRecruitingNCT05188859Phase 2
• Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingNCT05188508Phase 2
• Low Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyRecruitingNCT05187429Phase 1/2
• Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2
• Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)RecruitingNCT05185739Phase 2
• Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaEnrolling by invitationNCT05185505Phase 4
• Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
• Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2
• JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal CarcinomaRecruitingNCT05173246Phase 2
• A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant TumorsRecruitingNCT05170958Phase 1/2
• The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.RecruitingNCT05170542Phase 2
• Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction AdenocarcinomaRecruitingNCT05170503Phase 2
• Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver CancerRecruitingNCT05168163Phase 2
• Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingNCT05165407Phase 2
• Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.Not yet recruitingNCT05162898Not applicable
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2

← Immune Checkpoint Inhibitors overview